Hyper-CVAD Plus Ofatumumab Versus Hyper-CVAD Plus Rituximab as Frontline Therapy in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Hyper-CVAD Plus Ofatumumab Versus Hyper-CVAD Plus Rituximab as Frontline Therapy in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis
Cancer 2021 Sep 15;127(18)3381-3389, K Sasaki, HM Kantarjian, K Morita, NJ Short, M Konopleva, N Jain, F Ravandi, G Garcia-Manero, S Wang, JD Khoury, JL Jorgensen, RE Champlin, IF Khouri, P Kebriaei, HM Schroeder, M Khouri, R Garris, K Takahashi, SM O'Brien, EJ JabbourFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.